TrovaGene, Inc. (NASDAQ:TROV) hit a new 52-week low on Tuesday . The company traded as low as $0.60 and last traded at $0.60, with a volume of 268331 shares changing hands. The stock had previously closed at $0.63.

TROV has been the topic of a number of analyst reports. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a report on Wednesday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TrovaGene in a report on Tuesday, August 8th. Finally, lowered TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.

TrovaGene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The business had revenue of $0.12 million for the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%.

Institutional investors have recently modified their holdings of the stock. LMR Partners LLP acquired a new position in shares of TrovaGene during the 2nd quarter worth approximately $151,000. Susquehanna International Group LLP raised its position in shares of TrovaGene by 2,781.0% during the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after purchasing an additional 133,240 shares during the last quarter. KCG Holdings Inc. raised its position in shares of TrovaGene by 560.1% during the 1st quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after purchasing an additional 178,440 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of TrovaGene by 1,079.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after purchasing an additional 254,601 shares during the last quarter. Hedge funds and other institutional investors own 8.67% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “TrovaGene, Inc. (TROV) Sets New 1-Year Low at $0.60” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/trovagene-inc-trov-sets-new-1-year-low-at-0-60/1718275.html.

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.